HDAC9 and primary cutaneous T-cell lymphoma: HDAC inhibitors are presently approved for treatment of advanced primary cutaneous T-cell lymphoma (Mann et al, 2007), and have been shown to be effective in animal models of prostate cancer (Wedel et al, 2008).